World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 30 April 2018
Main ID:  EUCTR2014-004673-16-FR
Date of registration: 05/08/2015
Prospective Registration: Yes
Primary sponsor: F. Hoffmann-La Roche Ltd
Public title: Randomized, blinded, controlled study to compare the efficacy of treatment with tocilizumab with or without glucocorticoids in rheumatoid arthritis.
Scientific title: Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arthritis patients
Date of first enrolment: 16/11/2015
Target sample size: 226
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004673-16
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
Egypt France Germany Italy Lebanon Russian Federation Serbia Slovenia
Switzerland Tunisia Turkey
Contacts
Name: Trial Information Support Line-TISL   
Address:  Grenzacherstrasse 124 4070 Basel Switzerland
Telephone:
Email: global.rochegenentechtrials@roche.com
Affiliation:  F. Hoffmann-La Roche Ltd.
Name: Trial Information Support Line-TISL   
Address:  Grenzacherstrasse 124 4070 Basel Switzerland
Telephone:
Email: global.rochegenentechtrials@roche.com
Affiliation:  F. Hoffmann-La Roche Ltd.
Key inclusion & exclusion criteria
Inclusion criteria:
- Age >= 18 years
- RA of >= 6 months duration diagnosed according to American College of Rheumatology (ACR)/European League against Rheumatology (EULAR) criteria
Track TCZ-experienced patients:
- Have received tocilizumab (TCZ) either subcutaneous (SC, 162 milligrams [mg] once a week [QW]) or intravenous (IV, 8 mg/kilogram [kg] every 4 weeks [Q4W]) for the treatment of RA for at least 24 weeks prior to randomization
- Have received 5- 15 mg/day of glucocorticoids (GCs) [prednisone or equivalent] for the treatment of RA for at least 20 weeks prior to screening
- Currently receiving 5 mg/day of prednisone
- Have attained and maintained LDA (DAS28 ESR score <=3.2) or remission (DAS28 ESR score <=2.6) for at least 4 weeks prior to randomization
Track TCZ-naïve patients:
- Have active RA (defined as DAS28 ESR score >3.2)
- Are considered by the investigator as inadequate responders to conventional synthetic disease-modifying antirheumatic drug (csDMARDs) or biologic disease-modifying antirheumatic drug (bDMARDs)
- Are receiving 5-15 mg/day prednisone (or equivalent) for the treatment of RA

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 170
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 56

Exclusion criteria:
- Major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery during the study and up to 6 months after randomization
- Pregnant women or nursing (breastfeeding) mothers
- Body weight of >=150 kg
- RA of functional class IV, as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
- Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty syndrome). Secondary Sjögren syndrome with RA may be allowed per the discretion of the investigator
- Diagnosed with juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 years
- Prior or current inflammatory joint disease other than RA (e.g., gout, Lyme disease, sero-negative spondyloarthropathy, including reactive arthritis, psoriatic arthritis, arthropathy of inflammatory bowel disease), or prior or current joint infections
- Previous history of primary or secondary adrenal insufficiency
- Intraarticular (IA) or parenteral GCs for the treatment of RA within 4 weeks prior to screening
- Previous treatment with GCs for conditions other than RA, at any dose and in any formulation used continuously for > 1 week, during the last 1 year prior to screening. Topical GC creams or ointments for the treatment of skin conditions (e.g. eczema) are allowed
- Immunization with a live/attenuated vaccine within 30 days prior to screening
- Any previous treatment with alkylating agents such as chlorambucil or with total lymphoid irradiation
- Inadequate hematological, renal and liver functions
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Evidence of current serious uncontrolled cardiovascular (including uncontrolled hyperlipidemia), nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal (GI) disease
- Current liver disease as determined by the investigator
- History of diverticulitis, peptic ulcer disease, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn’s disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforations
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other opportunistic infections (including, but not limited to, tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, Epstein-Barr virus, cytomegalovirus and herpes zoster, but excluding fungal infections of nail beds)
- Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation
- Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
- Active TB requiring treatment within the previous 3 years (patients previously treated for TB with no recurrence within 3 years are permitted). All TCZ-naïve patients must be screened for latent TB and if positive, should be treated following local practice guidelines prior to initiating TCZ
- History of or currently active, primary or secondary immunodeficiency
- Evidence of active ma


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Intervention(s)

Trade Name: RoActemra 162 mg
Product Code: RO487-7533/F10-04
Pharmaceutical Form: Solution for injection
INN or Proposed INN: tocilizumab
CAS Number: 375823-41-9
Other descriptive name: TOCILIZUMAB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 180-

Trade Name: Prednisone Tablets USP, 5 mg
Product Code: RO001-9265/F04
Pharmaceutical Form: Capsule
INN or Proposed INN: Prednisone
Other descriptive name: PREDNISONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Trade Name: Prednisone Tablets USP, 1 mg
Product Code: RO 001-9265/F02-01
Pharmaceutical Form: Capsule
INN or Proposed INN: Prednisone
Other descriptive name: PREDNISONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Primary Outcome(s)
Main Objective: To compare the impact on disease activity of continued vs. tapered prednisone in RA patients with stable low disease activity (LDA [Disease Activity Score in 28 joints (DAS28) erythrocyte sedimentation rate (ESR) score <= 3.2]) or remission (DAS28 ESR score <= 2.6).
Primary end point(s): Change in DAS28 ESR between randomization and Week 24 post-randomization
Secondary Objective: -To compare the proportion of patients who continue vs. taper prednisone with LDA or remission at Week 24, who haven’t suffered a disease flare and showed no confirmed adrenal insufficiency requiring replacement therapy
-To compare between patients who continue vs. taper prednisone:(1)changes in CDAI and SDAI (2)the proportion of patients with >=1 flare; time to first flare; number of flares; >=1 administration of flare rescue medication; time to first administration, and number of administrations of flare rescue medication(3)cumulative prednisone exposure(4)the proportion of patients who maintain LDA or remission and who maintain the baseline disease activity level(5)proportion of patients who permanently discontinue study treatment due to insufficient flare control,(6)changes in the ACR core set, (7)identify predictors of successful prednisone dose-tapering(8)changes in patient-reported outcomes
-To evaluate the safety and tolerability of TCZ and proposed prednisone-tapering scheme
Timepoint(s) of evaluation of this end point: Randomization and Week 24
Secondary Outcome(s)
Secondary end point(s): 1 The proportion of patients with LDA (DAS28 ESR score <= 3.2) or remission (DAS28 ESR score <= 2.6) at Week 24 post-randomization, who have not suffered a disease flare and who showed no confirmed adrenal insufficiency that required replacement therapy
2 Change in clinical disease activity index (CDAI)/ simplified disease activity index (SDAI) between randomization and Week 24 post-randomization
3 The proportion or patients with >=1 flare, the time to first flare and the number of flares
4 The proportion of patients with >=1 administration of flare rescue medication, the time to first administration, and the number of administrations of flare rescue medication
5 Cumulative prednisone exposure (dose) between randomization and Week 24 post-randomization
6 The proportion of patients who maintain LDA (DAS28 ESR score <=3.2) or remission (DAS28 ESR score <=2.6) and the proportion of patients who maintain the baseline disease activity level at Week 24 post-randomization
7 The proportion of patients who permanently discontinue study treatment due to insufficient flare control
8 Changes in the ACR core set from randomization to post-randomization Week 24, including: swollen and tender joint counts; patient’s assessment of pain and global status; physician’s assessment of global status; Health assessment questionnaire–Disability index (HAQ-DI); and acute phase reactants (high sensitivity C-reactive protein [hsCRP] and ESR)
9 Incidence of adverse events (AEs) including non-serious and serious AEs, and AEs of special interest
10 Changes in vital signs, physical findings, and clinical laboratory results during and following TCZ administration
11 Assessment of immunogenicity (anti-TCZ antibodies)
12 Proportion of patients with confirmed adrenal insufficiency that required replacement therapy
13 Rheumatoid arthritis impact of disease (RAID) score
14 Work productivity and activity impairment questionnaire: Specific health problem (WPAI:SHP)
15 Health assessment questionnaire–Disability index (HAQ-DI) score
Timepoint(s) of evaluation of this end point: Week 24
2: From Randomization up to Week 24
3-4: Up to Week 24
5: From Randomization up to Week 24
6: Week 24
7: Up to Week 24
8: From Randomization up to Week 24
9-10: Up to Week 28
11: Up to Week 24 (performed on event driven basis)
12: Up to Week 24
13-14: Enrolment (Track TCZ-naïve patients only), randomization and Week 24
15: Randomization and Week 24
Secondary ID(s)
2014-004673-16-DE
MA29585
Source(s) of Monetary Support
F. Hoffmann-La Roche Ltd.
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history